Preempt future health risks.
In his latest op-ed for PharmaBoardroom, Dr Matt Linley, Airfinity's Senior Director for Analytics and Forecasting looks at the industry-defining breakthroughs expected in 2023 in the RSV market.Read More →
Bloomberg | Mar 10, 2023U.S. to lift covid testing requirements on travelers from China
The Washington Post | Mar 7, 2023Breakthrough Treatments Could Relegate RSV Seasons Like 2023 To History Books
PharmaBoardroom | Feb 15, 2023No new variants emerged from China’s Covid outbreak, study finds
NBC News | Feb 8, 2023
View All →
What's happening in a given disease area?
Airfinity is the most comprehensive, single source of intelligence for new developments in your chosen area.
Identify the true need for a vaccine or a treatment.
Our suite of dynamic predictive indicators help you navigate highly dynamic and uncertain market developments and see the real opportunities.
Maximise impact to save lives
Our analytics and probabilistic tools inform key decisions on resource allocation, investment and procurement decisions to maximise impact of a given drug or vaccine and ultimately improve as many lives as possible.
Airfinity combines proprietary surveillance tools and forecast models with expert analysis for dozens of infectious diseases, including COVID-19, Monkeypox, Influenza and RSV.
Market & Production
Disease & Prevalence
“The Airfinity report is a guide for world leaders to fix a more ambitious action plan.”
Gordon Brown, WHO Ambassador for Global Health Financing & former UK Prime Minister
“Airfinity has been instrumental in our country's COVID response.”
Head of UK Government
Vaccine Task Force
“Vaccine production data from Airfinity has been spot on. In a fast moving pandemic, these forecasts are really important for evidence-based policy making.”
“Airfinity has been critical in furnishing us and the rest of the world with COVID-19 numbers.”
James Fransham, Data Journalist,